There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biora Therapeutics (BIOR – Research Report), Irhythm Technologies (IRTC – Research Report) and Karyopharm Therapeutics (KPTI – Research Report) with bullish sentiments.
Biora Therapeutics (BIOR)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biora Therapeutics today and set a price target of $50.00. The company’s shares closed last Monday at $1.28, close to its 52-week low of $1.05.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of
Currently, the analyst consensus on Biora Therapeutics is a Moderate Buy with an average price target of $50.00.
See today’s best-performing stocks on TipRanks >>
Irhythm Technologies (IRTC)
Citi analyst Joanne Wuensch reiterated a Buy rating on Irhythm Technologies yesterday and set a price target of $110.00. The company’s shares closed last Monday at $112.91.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of
Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $126.40, a 18.1% upside from current levels. In a report issued on January 2, Wells Fargo also maintained a Buy rating on the stock with a $125.00 price target.
Karyopharm Therapeutics (KPTI)
H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics today and set a price target of $10.00. The company’s shares closed last Monday at $0.92, close to its 52-week low of $0.62.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $6.20 average price target, implying a 638.1% upside from current levels. In a report issued on January 3, RBC Capital also maintained a Buy rating on the stock with a $3.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIOR:
- Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
- Biora shares ‘reaching a key tipping point,’ says H.C. Wainwright
- Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
- Biora Therapeutics progresses research collaboration for BioJet platform
- Biora Therapeutics files to sell 71.07M shares of common stock for holders
